Overview of ZyVersa Therapeutics
ZyVersa Therapeutics, Inc. (OTCQB: ZVSA) is making strides in the development of innovative therapies aimed at addressing significant unmet medical needs in renal and inflammatory diseases. With a robust pipeline centered around two proprietary technologies—Cholesterol Efflux Mediator VAR 200 and Inflammasome ASC Inhibitor IC 100—ZyVersa is positioned to potentially revolutionize treatment options in these critical areas.
Financial Highlights for Q3 2025
In the third quarter of 2025, ZyVersa reported raising approximately $2.05 million, bringing the year-to-date total to approximately $4.05 million. As of September 30, 2025, the company had $0.5 million in cash and cash equivalents. This financial snapshot illustrates the crucial need for further financing to sustain ongoing operations and fund vital pipeline initiatives.
Operational Expenditure Breakdown
Research and development expenditures for the quarter were $0.4 million, representing a 16.3% decrease compared to the same period last year, largely attributed to reduced consultant costs. The decrease in general and administrative expenses, which totaled $1.7 million, reflects tighter management of resources, including lower insurance premiums and legal costs.
Understanding the Pipeline
ZyVersa’s lead product candidate, VAR 200, targets focal segmental glomerulosclerosis (FSGS), with future indications potentially encompassing Alport syndrome and diabetic kidney disease. Meanwhile, the development of IC 100 focuses on addressing cardiometabolic conditions, with prospects for expansion into rare kidney diseases.
Operating Loss Details
The company’s pre-tax losses in Q3 2025 amounted to $20.7 million, an increase from approximately $2.4 million in the previous year. This significant rise in loss was primarily due to an $18.6 million impairment related to in-process research and development, underscoring the impact of market capitalization fluctuations on project viability.
Future Financial Strategy
ZyVersa’s management is actively exploring various funding options, including both public and private equity, debt financing, and potential collaborations to support future development of their promising pipeline projects. The Company is committed to delivering cutting-edge treatments that could enrich the lives of patients suffering from unmet medical conditions.
Financial Position Insights
The total current assets as of late September 2025 stood at approximately $995,533, a considerable decrease from the previous year’s $1,715,797. This situation highlights the urgent need to strategically reallocate resources and enhance liquidity to meet operational obligations.
Company Contact Information
For further inquiries, please contact:
Karen Cashmere
Chief Commercial Officer
Email: kcashmere@zyversa.com
Phone: 786-251-9641
Frequently Asked Questions
What technologies does ZyVersa Therapeutics utilize?
ZyVersa Therapeutics focuses on Cholesterol Efflux Mediator VAR 200 and Inflammasome ASC Inhibitor IC 100 for developing treatments.
What were ZyVersa's financial results for Q3 2025?
The company raised approximately $2.05 million in Q3 2025 and reported a net loss of around $19.8 million.
Which conditions are targeted by ZyVersa's therapies?
ZyVersa's therapies target kidney diseases like FSGS and cardiometabolic conditions, with potential for expansion into rare diseases.
How is ZyVersa planning to fund its operations?
ZyVersa is exploring public and private equity options, debt financing, and partnerships for funding operational and development costs.
Who can I contact for more information about ZyVersa?
You can reach out to Karen Cashmere, Chief Commercial Officer, via email or phone for further details.
